CADL Stock Analysis: Buy, Sell, or Hold?
CADL - Candel Therapeutics, Inc. Common Stock
$10.18
0.70 (7.38%)
▲
5d:
+7.27%
30d:
+27.73%
90d:
+97.29%
BUY
MODERATE Confidence
Analysis Updated: Jul 17, 2026 12:00 AM ET
Earnings: Aug 13, 2026
25d
Get Alerted When CADL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CADL shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CADL shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CADL is currently trading at $10.18, which is considered extended relative to its 30-day fair value range of $8.56 to $10.02. From a valuation perspective, the stock is trading at a discount (Forward PE: -16.8) compared to its historical average (40.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $9.19, while resistance sits at $10.50. The stock is showing strong short-term momentum, up 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.50 (+101.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $9.19, while resistance sits at $10.50. The stock is showing strong short-term momentum, up 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.50 (+101.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.56 -
$10.02
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.4%)
- BULLISH: Trading 101.4% below Wall St target ($20.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$8.56 -
$10.02
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.19
Resistance Level
$10.50
Current Trend
Strong Uptrend
Technical data as of
Jul 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.83
Wall Street Target
$20.50
(+101.4%)
PE vs Historical
-16.8 vs 40.5
CHEAP
Share & Embed Analysis
Last updated: July 18, 2026 5:25 PM ET
Data refreshes hourly during market hours. Next update: 6:25 PM
Data refreshes hourly during market hours. Next update: 6:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CADL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Paul B Manning
BUY
550458 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 60 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
